Adalimumab Effective in JIA-Associated Uveitis Unresponsive to Methotrexate
Adalimumab was well tolerated and associated with persistent uveitis improvement in most cases.
Adalimumab was well tolerated and associated with persistent uveitis improvement in most cases.
These results indicate superiority of adalimumab vs standard of care in the treatment of severe uveitis cases.
Patients with panuveitis more often had biopsy-confirmed sarcoidosis than those with other anatomical locations of uveitis (20% vs 4%).
At seven-year follow-up, visual acuity was better with systemic therapy than with intravitreous fluocinolone acetonide implants.
In children with active juvenile idiopathic arthritis, the treatment combination controls eye inflammation.
Patients with severe psoriasis and those with mild psoriasis and concomitant psoriatic arthritis have an increased risk of uveitis.
Researchers examined whether different TNF inhibitors were associated with different rates of anterior uveitis in patients with ankylosing spondylitis undergoing treatment with adalimumab, etanercept, or infliximab.
Tocilizumab therapy showed rapid improvement in ocular parameters for uveitis in juvenile idiopathic arthritis patients.
Uveitis may be the main source of the primary disease’s symptoms, which indicates the importance of interdisciplinary collaboration between ophthalmologists and rheumatologists in evaluating and treating such patients.
Most commonly used to treat chronic uveitis, weekly adalimumab was linked to a positive clinical response in 93% of patients.